EUVIMEDEUVIMED entdecken
Crossref

Invited commentary: building rigorous clinical evidence for drug–drug interactions

Paraskevi Tassopoulou, Antonios Douros iD

American Journal of Epidemiology · 2025

DOI: 10.1093/aje/kwaf222 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Epidemiology, 2025. Verfasst von Paraskevi Tassopoulou und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Pharmacology and Toxicology, Charité - Universitätsmedizin Berlin, Berlin, Germany. Hauptthemen laut MEDLINE: Analgesics, Opioid, Hydrocodone, Calcium Channel Blockers. Die Arbeit nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug–drug interactions (DDIs) are a major cause of preventable adverse drug events. However, the clinical relevance of specific DDIs is often uncertain due to limited evidence beyond preclinical findings and pharmacokinetic studies. In this editorial, we discuss the recent study by Bea et al. (Am J Epidemiol. 2025;000(00):0000-0000), which assessed whether the pharmacologic interaction between hydrocodone and non-dihydropyridine calcium-channel blockers is associated with the risk of opioid overdose, finding no increased risk. We highlight the methodological strengths of the study, including the use of a control precipitant, the consideration of the order of drug initiation in concomitant use, and the application of multiple exposure definitions. At the same time, we outline remaining challenges—both in this study and more broadly in the DDI field—such as the appropriate selection of control precipitants and selection bias due to depletion of susceptibles. Finally, we briefly discuss potential applications of novel pharmacoepidemiologic methods for DDI studies and also ways to strengthen the rationale for DDI studies and prioritize study questions. Given the rising rates of polypharmacy that lead to increased concomitant use of medications potentially interacting with each other, pharmacoepidemiology is well positioned to generate clinically actionable evidence to guide medication safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Analgesics, OpioidHydrocodoneCalcium Channel BlockersDrug InteractionsHumansPharmacoepidemiologyDrug OverdoseDrug-Related Side Effects and Adverse Reactions

Stichwörter der Autor:innen

drug safetypharmacoepidemiologyreal-world evidence

Substanzen

Analgesics, OpioidHydrocodoneCalcium Channel Blockers

Autor:innen und Institutionen

  • Institute of Clinical Pharmacology and Toxicology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada.
  • School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada.

ORCID-Profile: Antonios Douros

Zitieren

APA

Tassopoulou, P., & Douros, A. (2025). Invited commentary: building rigorous clinical evidence for drug–drug interactions. American Journal of Epidemiology. https://doi.org/10.1093/aje/kwaf222

Vancouver

Tassopoulou P, Douros A. Invited commentary: building rigorous clinical evidence for drug–drug interactions. American Journal of Epidemiology. 2025. doi:10.1093/aje/kwaf222

BibTeX
@article{Tassopoulou2025,
  author = {Tassopoulou, Paraskevi and Douros, Antonios},
  title = {Invited commentary: building rigorous clinical evidence for drug–drug interactions},
  journal = {American Journal of Epidemiology},
  year = {2025},
  doi = {10.1093/aje/kwaf222}
}
Kostenlos starten →